Title:
PTH産生に対する被験物質の作用をアッセイする方法
Document Type and Number:
Japanese Patent JP5154609
Kind Code:
B2
Abstract:
The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensiing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc.
The symbols in the formula represent the following meanings:
Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused;
R 1 : a group selected from the group consisting of
optionally substituted cyclic hydrocarbon group, and
optionally substituted heterocyclic group;
n: an integer of 1 to 3;
X: single bonding arm, -CH 2 -, -CO- , - (CH 2 ) m -CO- ,
-CH (R 2 ) -CO-, - (CH 2 ) p -Y-(C(R 3 ) (R 4 )) q -CO-, -NH-CO- or
-N(R 5 ) -CO-;
in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R 1 ;
m is an integer of 1 to 3;
p is an integer of 0 to 2;
q is an integer of 0 to 2;
Y: -O- or -SO 2 -;
R 2 : phenyl or lower alkyl;
R 3 , R 4 : each independently represents hydrogen atom or lower alkyl;
R 5 : lower alkyl;
provided that the ring portion of the group represented by R 1 is neither naphthylidine nor partially saturated group thereof, and, when X is -CH 2 - or -CO-, R 1 is not naphthyl.
More Like This:
Inventors:
Hiroshi Miyazaki
Junko Tsubakimoto
Kosuke Yasuda
Iwao Takamuro
Osamu Sakurai
Tetsuya Yanagita
Yuu Kuno
Junko Tsubakimoto
Kosuke Yasuda
Iwao Takamuro
Osamu Sakurai
Tetsuya Yanagita
Yuu Kuno
Application Number:
JP2010161413A
Publication Date:
February 27, 2013
Filing Date:
July 16, 2010
Export Citation:
Assignee:
Mitsubishi Tanabe Pharma Corporation
International Classes:
C12Q1/02; A61K31/397; A61K31/40; A61K31/402; A61K31/4025; A61K31/404; A61K31/415; A61K31/4184; A61K31/4192; A61K31/427; A61K31/4439; A61K31/445; A61K31/451; A61K31/4545; A61K31/4709; A61K31/496; A61K31/497; A61K31/501; A61K31/502; A61K31/506; A61K31/5377; A61K31/5415; A61P5/20; A61P43/00; C07D205/04; C07D207/14; C07D207/16; C07D207/27; C07D207/327; C07D207/335; C07D207/34; C07D211/56; C07D401/04; C07D401/06; C07D401/10; C07D401/12; C07D403/04; C07D403/06; C07D403/10; C07D405/12; C07D409/06; C07D409/12; C07D417/04; C07D417/06; C07D207/26; C07D207/32; C07K14/635
Domestic Patent References:
| JP2001220356A | ||||
| JP11221095A |
Other References:
Clinical Calcium,2001年,Vol.11, No.8,p.1044-1047
Attorney, Agent or Firm:
Hajime Tsukuni
Fusayuki Saito
Fusayuki Saito